Expression of proto-oncogene c-kit in high risk prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of proto-oncogene c-kit in high risk prostate cancer

Published:2004-11 Issue:9 Volume:30 Page:987-992
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology (EJSO)
language:en
Short-container-title:European Journal of Surgical Oncology (EJSO)

Author:

Di Lorenzo G.,Autorino R.,D'Armiento F.P.,Mignogna C.,De Laurentiis M.,De Sio M.,D'Armiento M.,Damiano R.,Vecchio G.,De Placido S.

Publisher

Elsevier BV

Subject

Oncology,General Medicine,Surgery

Reference31 articles.

1. Treatment of prostate cancer—the clinical use of radical prostatectomy;Noldus;EAU Update Ser,2003

2. Treatment of localized or locally advanced prostate cancer: the clinical use of radiotherapy;Bolla;EAU Update Ser,2003

3. Long term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience;Han;Urol Clin North Am,2001

4. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database;Grossfeld;J Urol,1998

5. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis;Gerber;Eur Urol,1997

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MYH6 suppresses tumor progression by downregulating KIT expression in human prostate cancer;Scientific Reports;2024-08-24

2. The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens;Biomedicines;2024-07-23

3. Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX;Clinics and Practice;2024-03-19

4. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide;The Prostate;2023-04-27

5. The Interrelationship Between FYN and miR-128/193a-5p/494 in Imatinib Resistance in Prostate Cancer;Anti-Cancer Agents in Medicinal Chemistry;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3